Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antisense
Biotech
AAIC: Biogen bolsters hopes for pivotal anti-tau push
Biogen plans to rapidly move the antisense oligonucleotide diranersen into a phase 3 study, but hasn't committed to a dose just yet.
Darren Incorvaia
Jul 14, 2026 9:15am
Ionis bags $30M from Recordati for ex-US rare disease rights
Jun 25, 2026 6:59am
Biogen advances Alzheimer’s tau program despite midphase miss
May 14, 2026 8:35am
Biogen links up with Alloy platform to boost ASO drug development
Apr 7, 2026 6:00am
GSK pays $17.5M for CAMP4 regulatory RNA deal
Dec 18, 2025 7:00am
Fierce Pharma
Sarepta, despite key trial flop, will seek full nod for DMD meds
Nov 4, 2025 7:56am
